Trial reportAmerican journal of respiratory and critical care medicine2018
A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (LIBERATE).
Trial report in American journal of respiratory and critical care medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 177 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Zephyr Valve Registry
Zephyr Etude Post-Inscription (French Registry)
Who cites it
177 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Pooled it
- The effects of lung volume reduction treatment on diffusing capacity and gas exchange.European respiratory review : an official journal of the European Respiratory Society · 2020Pooled it
- Expert Statement: Pneumothorax Associated with One-Way Valve Therapy for Emphysema: 2020 Update.Respiration; international review of thoracic diseasesGuideline
- Visual feedback using electrical impedance tomography during inhalation therapy for chronic obstructive lung disease: a pilot study.Scientific reports · 2026Trial
- Randomized Sham-controlled Trial of Targeted Lung Denervation in Patients with Chronic Obstructive Pulmonary Disease (AIRFLOW-3).American journal of respiratory and critical care medicine · 2025Trial
- Airway Scaffolds for Emphysema-related Hyperinflation: Six-Month Results from the BREATHE Trial.American journal of respiratory and critical care medicine · 2025Trial
- Sustained Clinical Benefits of Spiration Valve System in Patients with Severe Emphysema: 24-Month Follow-Up of EMPROVE.Annals of the American Thoracic Society · 2024Trial
- Lung volume reduction surgeryThe European respiratory journal · 2023Trial
- Endobronchial coils for emphysema: Dual mechanism of action on lobar residual volume reduction.Respirology (Carlton, Vic.) · 2020Trial
- Effect of Zephyr Endobronchial Valves on Dyspnea, Activity Levels, and Quality of Life at One Year. Results from a Randomized Clinical Trial.Annals of the American Thoracic Society · 2020Trial
- Improving Lung Function in Severe Heterogenous Emphysema with the Spiration Valve System (EMPROVE). A Multicenter, Open-Label Randomized Controlled Clinical Trial.American journal of respiratory and critical care medicine · 2019Trial
- The REACH Trial: A Randomized Controlled Trial Assessing the Safety and Effectiveness of the Spiration® Valve System in the Treatment of Severe Emphysema.Respiration; international review of thoracic diseases · 2019Trial
- Endobronchial Valve (Zephyr) Treatment in Homogeneous Emphysema: One-Year Results from the IMPACT Randomized Clinical Trial.Respiration; international review of thoracic diseasesTrial
- Artificial intelligence and digital health in bronchoscopy: advances in diagnostic accuracy, real-time navigation and procedural skills training.Breathe (Sheffield, England) · 2026Review
- Remimazolam for Zephyr Endobronchial Valve Placement in a Severe Chronic Obstructive Pulmonary Disease Patient: A Case Report.Clinical case reports · 2026Article
- Advancing Precision Approaches to Chronic Obstructive Pulmonary Disease.Tuberculosis and respiratory diseases · 2026Review
- Connecting the dots: historical perspective on lung volume reduction.Journal of thoracic disease · 2026Review
- Observational
- Endobronchial Valves for Bronchoscopic Lung Volume Reduction in Severe Emphysema: A Reversible and Non-Surgical Treatment for Patients Who May or May Not Be Candidates for Lung Transplantation.Diagnostics (Basel, Switzerland) · 2026Review
- A Brief History of COPD: As Told by Some of Its Senior Scientists and Clinicians.Journal of clinical medicine · 2026Review
117 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
29 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleThis is the first multicenter randomized controlled trial to evaluate the effectiveness and safety of Zephyr Endobronchial Valve (EBV) in patients with little to no collateral ventilation out to 12 months.
objectivesTo evaluate the effectiveness and safety of Zephyr EBV in heterogeneous emphysema with little to no collateral ventilation in the treated lobe.
methodsSubjects were enrolled with a 2:1 randomization (EBV/standard of care [SoC]) at 24 sites. Primary outcome at 12 months was the ΔEBV-SoC of subjects with a post-bronchodilator FEV MEASUREMENTS AND MAIN
resultsA total of 190 subjects (128 EBV and 62 SoC) were randomized. At 12 months, 47.7% EBV and 16.8% SoC subjects had a ΔFEV
conclusionsZephyr EBV provides clinically meaningful benefits in lung function, exercise tolerance, dyspnea, and quality of life out to at least 12 months, with an acceptable safety profile in patients with little or no collateral ventilation in the target lobe. Clinical trial registered with www.clinicaltrials.gov (NCT 01796392).
Indexed as
Identifiers
29787288What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.